Compare UGP & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGP | IBRX |
|---|---|---|
| Founded | 1937 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.5B |
| IPO Year | 2001 | 2015 |
| Metric | UGP | IBRX |
|---|---|---|
| Price | $5.73 | $7.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $5.37 | ★ $12.57 |
| AVG Volume (30 Days) | 2.3M | ★ 11.5M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $9.93 | $88.59 |
| Revenue Next Year | $3.25 | $131.15 |
| P/E Ratio | $9.99 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $2.80 | $1.95 |
| 52 Week High | $6.20 | $12.43 |
| Indicator | UGP | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 52.14 |
| Support Level | $5.65 | $7.77 |
| Resistance Level | $6.14 | $8.42 |
| Average True Range (ATR) | 0.16 | 0.50 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 19.83 | 62.24 |
Ultrapar Participacoes SA engages in the investment of its own capital in services, commercial, and industrial activities, through the subscription or acquisition of shares of other companies. The company's business segments include: i) Ultragaz distributes LPG in the segments: bulk, comprising condominiums, trade, services, industries, and agribusiness; and bottled, mainly comprising residential consumers. ii) Ipiranga, the majority revenue generating segment, engages in the distribution and sale of oil-related products to service stations that operate under the Ipiranga brand throughout Brazil. iii) Ultracargo operates in specialized liquid bulk storage solutions in the main logistics centers. iv) Hidrovias: operates in logistics solutions and waterway and multimodal infrastructure.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.